全文获取类型
收费全文 | 2734篇 |
免费 | 142篇 |
国内免费 | 205篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 63篇 |
妇产科学 | 23篇 |
基础医学 | 400篇 |
口腔科学 | 11篇 |
临床医学 | 248篇 |
内科学 | 865篇 |
皮肤病学 | 15篇 |
神经病学 | 161篇 |
特种医学 | 29篇 |
外科学 | 205篇 |
综合类 | 315篇 |
预防医学 | 260篇 |
眼科学 | 7篇 |
药学 | 340篇 |
中国医学 | 62篇 |
肿瘤学 | 46篇 |
出版年
2023年 | 26篇 |
2022年 | 56篇 |
2021年 | 70篇 |
2020年 | 77篇 |
2019年 | 89篇 |
2018年 | 84篇 |
2017年 | 54篇 |
2016年 | 70篇 |
2015年 | 52篇 |
2014年 | 175篇 |
2013年 | 213篇 |
2012年 | 127篇 |
2011年 | 169篇 |
2010年 | 146篇 |
2009年 | 130篇 |
2008年 | 169篇 |
2007年 | 145篇 |
2006年 | 149篇 |
2005年 | 115篇 |
2004年 | 104篇 |
2003年 | 92篇 |
2002年 | 66篇 |
2001年 | 51篇 |
2000年 | 43篇 |
1999年 | 46篇 |
1998年 | 43篇 |
1997年 | 31篇 |
1996年 | 33篇 |
1995年 | 44篇 |
1994年 | 44篇 |
1993年 | 43篇 |
1992年 | 35篇 |
1991年 | 37篇 |
1990年 | 24篇 |
1989年 | 24篇 |
1988年 | 33篇 |
1987年 | 16篇 |
1986年 | 19篇 |
1985年 | 26篇 |
1984年 | 16篇 |
1983年 | 7篇 |
1982年 | 11篇 |
1981年 | 11篇 |
1980年 | 8篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 6篇 |
1975年 | 8篇 |
1973年 | 6篇 |
排序方式: 共有3081条查询结果,搜索用时 15 毫秒
1.
2.
孕烷X受体(Pregnane X receptor,PXR)是核受体家族成员之一,可被多种内源性和外源性物质激活。PXR通过诱导药物代谢酶和转运体,在肝脏、肠道、皮肤和血管内皮中发挥重要的解毒作用。此外,PXR还具有调节糖脂代谢、胆固醇代谢、胆红素和胆汁酸代谢、免疫炎症反应等功能。研究证实,PXR已被公认为多种炎症性疾病的有效药物干预靶点,如炎性结肠炎、坏死性肠炎、肝炎、皮炎、糖尿病等。多种中药或其活性成分可以作为PXR受体激动剂通过核因子B(NF-κB)和尾部相关同源盒转录因子2(Cdx2)通路干扰炎症反应,如虎杖、木蝴蝶、黄芩、黄连、丹参、白芷、人参、香附、五味子、高良姜等。本文综述了近年来PXR调节炎症反应的最新研究成果以及中药激活PXR干预炎症反应的机制,以期为今后的研究提供参考。 相似文献
3.
4.
5.
6.
7.
8.
9.
BackgroundAccumulating evidence suggests that statins have a beneficial effect on breast cancer prognosis. Previous studies have reported a positive association between statin use and breast cancer survival; however, the relationship between statin use and patterns of breast cancer recurrence remains unclear.Patients and methodsWe identified all Malmö Diet and Cancer Study (MDCS) participants diagnosed with incident invasive breast cancer between 2005 and 2014. The follow-up period began at breast cancer diagnosis and continued until the first invasive breast cancer recurrence event, death, emigration or the end of the follow-up (June 8, 2020). We estimated incidence rates (IRs) of recurrence and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) for disease recurrence to compare post-diagnosis statin users with non-users.ResultsThe final study cohort consisted of 360 eligible patients with a median follow-up of 8.6 years. Overall, there were 71 recurrences in 2932 total person-years. According to statin use, there were 14 recurrences in 595 person-years among statin users, and 57 recurrences in 2337 person-years in non-users. Statin use was associated with a reduced risk of breast cancer recurrence (HRadj = 0.88 [95% CI: 0.82–0.96]). Regarding the pattern of recurrence, statin use was associated with a reduced risk of distant recurrence (HRadj = 0.86 [95% CI: 0.80–0.94]) but not loco-regional recurrence (HRadj = 0.97 [95% CI: 0.87–1.08]).ConclusionIn the MDCS, statin use was associated with a reduced risk of distant breast cancer recurrence, whereas no association between statin use and loco-regional breast cancer recurrence was found. This site-based difference in disease recurrence may be explained by statin's inhibition of epithelial-mesenchymal transition. 相似文献
10.
《Vaccine》2016,34(11):1370-1378
Tuberculosis (TB) is a serious disease around the world, and protein based subunit vaccine is supposed to be a kind of promising novel vaccine against it. However, there is no effective adjuvant available in clinic to activate cell-mediated immune responses which is required for TB subunit vaccine. Therefore, it is imperative to develop new adjuvant. Here we reported an adjuvant composed of dimethyl dioctadecylammonium (DDA), Poly I:C and cholesterol (DPC for short). DDA can form a kind of cationic liposome with the ability to deliver and present antigen and can induce Th1 type cell-mediated immune response. Poly I:C, a ligand of TLR3 receptor, could attenuate the pathologic reaction induced by following Mycobacterium tuberculosis challenge. Cholesterol, which could enhance rigidity of lipid bilayer, is added to DDA and Poly I:C to improve the stability of the adjuvant. The particle size and Zeta-potential of DPC were analyzed in vitro. Furthermore, DPC was mixed with a TB fusion protein ESAT6-Ag85B-MPT64(190-198)-Mtb8.4-Rv2626c (LT70) to construct a subunit vaccine. The subunit vaccine-induced immune responses and protective efficacy against M. tuberculosis H37Rv infection in C57BL/6 mice were investigated. The results showed that the DPC adjuvant with particle size of 400 nm and zeta potential of 40 mV was in good stability. LT70 in the adjuvant of DPC generated strong antigen-specific humoral and cell-mediated immunity, and induced long-term higher protective efficacy against M. tuberculosis infection (5.41 ± 0.38 log10 CFU) than traditional vaccine Bacillus Calmette–Guerin (BCG) (6.01 ± 0.33 log10 CFU) and PBS control (6.53 ± 0.26 log10 CFU) at 30 weeks post-vaccination. In conclusion, DPC would be a promising vaccine adjuvant with the ability to stimulate Th1 type cell-mediated immunity, and could be used in TB subunit vaccine. 相似文献